Nerve Tissue Or Nerve Cell Growth Affecting Patents (Class 514/8.3)
  • Patent number: 9943549
    Abstract: The present invention provides a method for isolating human neural stem cells from amniotic fluid of a patient whose fetus has been diagnosed to have a neural tube defect. Use of the isolated human neural stem cells in the treatment of neurological disorders is also provided.
    Type: Grant
    Filed: March 17, 2015
    Date of Patent: April 17, 2018
    Assignee: FOOD INDUSTRY RESEARCH AND DEVELOPMENT INSTITUTE
    Inventors: Shiaw-Min Hwang, Yu-Jen Chang, Lee-Feng Hsu
  • Patent number: 9884045
    Abstract: The present invention provides a transplantation adjuvant for neural progenitor cells containing valproic acid and/or zonisamide as an active ingredient.
    Type: Grant
    Filed: November 14, 2013
    Date of Patent: February 6, 2018
    Assignee: Sumitomo Dainippon Pharma Co., Ltd.
    Inventor: Jun Takahashi
  • Patent number: 9592234
    Abstract: The present invention provides methods and compositions comprising compounds useful for stimulating neurogenesis. The methods and compositions comprising compounds are also useful for inhibiting neuronal degeneration. Thus, the present invention can be used in the treatment of diseases and conditions characterized by neuronal loss and reduced neurogenesis including Alzheimer's disease, stroke, traumatic brain injury, traumatic nerve injury, and depression. This invention is useful for research products including single agents or mixtures of agents to promote, proliferate, differentiate, or maintain neurons from stem or progenitor cells.
    Type: Grant
    Filed: June 26, 2015
    Date of Patent: March 14, 2017
    Assignee: Neuronascent, Inc.
    Inventor: Judith Kelleher-Andersson
  • Patent number: 9517221
    Abstract: [Problem to be solved] Provision of an agent for preventing or treating a functional brain disease and/or inhibiting symptom development of the same. [Means for solving the problems] An agent for preventing or treating a functional brain disease and/or inhibiting symptom development of the same, which comprises (2R)-2-propyloctanoic acid or a salt thereof. The agent for preventing or treating a functional brain disease and/or inhibiting symptom development of the same, which comprises (2R)-2-propyloctanoic acid or a salt thereof, can be safely administered to patients of, for example, functional brain diseases such as depression, menopausal mood disorder, perimenopausal mood disorder, panic disorder, irritable bowel syndrome, social anxiety disorder, post-traumatic stress disorder or the like, and also can show excellent effects.
    Type: Grant
    Filed: March 8, 2007
    Date of Patent: December 13, 2016
    Assignee: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Rika Shinagawa, Yoshifumi Kagamiishi, Taiji Shimoda
  • Patent number: 9464129
    Abstract: The invention relates to peptides of general formula (I): R1-AA-R2??(I) which can regulate neuronal exocytosis, their stereoisomers and racemic or non-racemic mixtures thereof, and the cosmetically or pharmaceutically acceptable salts thereof, wherein AA is a sequence of 3 to 40 adjacent amino acids contained in the amino acid sequence of the SNAP-25 protein, R1 is selected from the group consisting of H or alkyl, aryl, aralkyl or acyl group; and R2 is selected from the group consisting of amino, hydroxyl or thiol, substituted or non-substituted with aliphatic or cyclic groups, with the condition that when R1 is H or acetyl, R2 is not non-substituted amino, hydroxyl or thiol. The invention also relates to a method of obtaining such peptides, cosmetic or pharmaceutical compositions containing them and their use to treat those conditions requiring neuronal exocytosis regulation, preferably for treating the skin.
    Type: Grant
    Filed: October 24, 2007
    Date of Patent: October 11, 2016
    Assignee: BCN PEPTIDES S.A.
    Inventors: Cristina Carreño Serraïma, Berta Ponsati Obiols, Wim Van Den Nest, Jimena Fernandez Carneado, Antonio Ferrer Montiel, Juan Cebrian Puche, Nuria Almiñana Domenech
  • Patent number: 9365620
    Abstract: The invention provides agents useful for treating pain. An exemplary agent comprises or consists of the a portion of a retroviral Tat protein. One such agent is the peptide Tat-NR2B9c. This peptide has previously been described as an agent for inhibiting damaging effects of stroke and similar conditions via inhibition of PSD95 interactions with NMDA receptors and/or NOS. The present application provides data showing that the Tat-NR2B9c peptides is effective in alleviation of pain. The alleviation of pain can be obtained at a dose of the peptide below the dose required to inhibit PSD-95 interactions with NMDAR or NOS.
    Type: Grant
    Filed: May 9, 2014
    Date of Patent: June 14, 2016
    Assignee: NoNO Inc.
    Inventors: Michael P. Belmares, Jonathan David Garman, Peter S. Lu, Michael W. Salter, Michael Tymianski
  • Patent number: 9297815
    Abstract: A method for detecting a condition in a patient with disturbance of consciousness, by analyzing an amount and/or activity of a von Willebrand factor-cleaving protease, and a kit for detecting a condition in a patient with disturbance of consciousness, comprising an antibody or a fragment thereof which specifically binds to a von Willebrand factor-cleaving protease, or a von Willebrand factor or a fragment thereof, are disclosed. Examples of the detection of a condition include a detection of cerebrovascular disease, a detection of arteriosclerotic vascular disease, and a detection or prediction of severity.
    Type: Grant
    Filed: February 15, 2007
    Date of Patent: March 29, 2016
    Assignee: LSI MEDIENCE CORPORATION
    Inventors: Ko Igami, Tomoharu Okazaki, Koichi Shinmyozu, Tomoko Ono, Fumio Furusaki
  • Patent number: 9127083
    Abstract: Neurturin polypeptides which possess reduced heparin and heparan sulfate binding affinity but retain neurotrophic activity, nucleic acids which encode the neurturin variants and vectors and host cells which express the enhanced neurturin polypeptides. Use of the enhanced neurturin polypeptides, nucleic acids and host cells in the treatment or prevention of disease.
    Type: Grant
    Filed: March 18, 2013
    Date of Patent: September 8, 2015
    Assignee: NTF Therapeutics, Inc.
    Inventors: Pia Runeberg-Roos, Maxim M. Bespalov, Richard Penn, Mart Saarma
  • Patent number: 9080151
    Abstract: A method of differentiating embryonic stem cells into neural and motor cells is disclosed. In one embodiment, the invention comprises culturing a population of cells comprising a majority of cells that are characterized by an early rosette morphology and are Sox1?/Pax6+ in the presence of FGF2, FGF4, FGF8, FGF 9, or RA wherein the cells are characterized by an neural tube-like rosette morphology and are Pax6+/Sox1+.
    Type: Grant
    Filed: May 6, 2011
    Date of Patent: July 14, 2015
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Su-Chun Zhang, Xue-jun Li
  • Publication number: 20150142026
    Abstract: The instant invention provides electrospun fiber compositions comprising one or more polymers and one or more biologically active agents. In specific embodiments, the biologically active agents are nerve growth factors. In certain embodiments, the electrospun fiber compositions comprising one or more biologically active agents are on the surface of a film, or a tube. The tubes comprising the electrospun fiber compositions of the invention can be used, for example, as nerve guide conduits.
    Type: Application
    Filed: January 26, 2015
    Publication date: May 21, 2015
    Inventors: Ahmet Hoke, Sing Y. Chew, Ruifa Mi, Kam W. Leong
  • Patent number: 9029323
    Abstract: The present invention relates to neurturin protein products conjugated to polyols and to pharmaceutical compositions comprising neurturin conjugates as active ingredients, preferably PEGylated neurturin conjugates or variants thereof, having increased bioavailability.
    Type: Grant
    Filed: May 5, 2010
    Date of Patent: May 12, 2015
    Assignee: Evotec International GmbH
    Inventors: Matthias Austen, Marcus Geese, Rainer Mussmann, Friedrich Harder, Thomas Siegmund, Martin Schneider
  • Patent number: 9023800
    Abstract: Isolated DJ-1 related peptides are disclosed and pharmaceutical compositions comprising same for treating oxidative stress-related disorder.
    Type: Grant
    Filed: April 23, 2012
    Date of Patent: May 5, 2015
    Assignee: Ramot at Tel-Aviv University Ltd.
    Inventors: Daniel Offen, Nirit Lev, Eldad Melamed
  • Publication number: 20150110875
    Abstract: Bolaamphiphilic compounds are provided according to formula I: HG2-L1-HG1??I where HG1, HG2 and L1 are as defined herein. Provided bolaamphilphilic compounds and the pharmaceutical compositions thereof are useful for delivering GDNF or NGF into animal or human brain.
    Type: Application
    Filed: July 10, 2014
    Publication date: April 23, 2015
    Inventors: Charles LINDER, Sarina GRINBERG, Eliahu HELDMAN
  • Patent number: 9012400
    Abstract: Neuregulin peptides useful in, for example, methods and compositions comprising preventing, treating or delaying various diseases or disorders are described.
    Type: Grant
    Filed: December 9, 2013
    Date of Patent: April 21, 2015
    Assignee: Zensun (Shanghai) Science & Technology Ltd.
    Inventor: Mingdong Zhou
  • Publication number: 20150094263
    Abstract: The disclosure provides compositions and methods for preventing, ameliorating a sign or symptom of, or treating peripheral nerve injury.
    Type: Application
    Filed: March 29, 2013
    Publication date: April 2, 2015
    Inventors: Anthony O. Caggiano, Anthony J. Bella, Anindita Ganguly, Jennifer Iaci, Thomas Parry, Raymond Warren Colburn
  • Publication number: 20150080302
    Abstract: The present invention relates to new therapeutic and diagnostic uses of soluable neuregulin-1 isoforms and polypeptides, particularly neurological disorders.
    Type: Application
    Filed: November 21, 2014
    Publication date: March 19, 2015
    Inventors: Thierry Baussant, Daniel Bach, André Schrattenholz
  • Patent number: 8962553
    Abstract: The present invention relates to PEGylated C-peptide derivatives comprising at least one PEG group attached to the N-terminus, which exhibit improved pharmacokinetic and biological activity in vivo.
    Type: Grant
    Filed: November 19, 2012
    Date of Patent: February 24, 2015
    Assignee: Cebix AB
    Inventors: John Wahren, Sheri Barrack, James Callaway, Michelle Mazzoni, Howard Foyt, Mark Daniels
  • Publication number: 20150044139
    Abstract: The present application relates to use of a Midkine family protein for growing hair on a mammal, or in the manufacture of a medicament for growing hair on a mammal, especially for treatment or prevention of different forms of alopecia.
    Type: Application
    Filed: August 20, 2014
    Publication date: February 12, 2015
    Inventors: Sadatoshi Sakuma, Maria Halasz, Darren Jones
  • Patent number: 8946151
    Abstract: A method of treating Parkinson's disease in humans is disclosed, wherein glial cell-line derive neurotrophic factor (GDNF) is chronically administered directly to one or both putamen of a human in need of treatment thereof via convection-enhanced infusion using at least one implantable pump and at least one catheter. In one aspect of the present invention the GDNF is infused directly into one or both putamen through one or more indwelling intraparenchymal multiport brain catheters connected to one or more implantable pumps wherein the flow rate is pulsed.
    Type: Grant
    Filed: October 13, 2004
    Date of Patent: February 3, 2015
    Assignees: Northern Bristol N.H.S. Trust Frenchay Hospital, University of Kentucky Research Foundation, Amgen Inc.
    Inventors: Steven S. Gill, Don M. Gash, Greg A. Gerhardt
  • Patent number: 8946152
    Abstract: A method of treating Parkinson's disease in humans is disclosed, wherein glial cell-line derive neurotrophic factor (GDNF) is chronically administered directly to one or both putamen of a human in need of treatment thereof via convection-enhanced infusion using at least one implantable pump and at least one catheter. In one aspect of the present invention the GDNF is infused directly into one or both putamen through one or more indwelling intraparenchymal mutitiport brain catheters connected to one or moreimplantable pumps wherein the flow rate is pulsed.
    Type: Grant
    Filed: September 22, 2005
    Date of Patent: February 3, 2015
    Assignees: Amgen Inc., University of Kentucky Research Foundation
    Inventors: Steven S. Gill, Don M. Gash, Greg Allen Gerhardt
  • Publication number: 20150024025
    Abstract: Embodiments of the present disclosure provide for aligned nanofibrous polymer matrix structure, structures incorporating aligned nanofibrous polymer matrix structures, methods of using aligned nanofibrous polymer matrix structures, methods of making aligned nanofibrous polymer matrix structures, and the like.
    Type: Application
    Filed: March 6, 2013
    Publication date: January 22, 2015
    Applicant: The UABB Research Foundation
    Inventor: Candace Floyd
  • Publication number: 20150023971
    Abstract: The present invention provides agents for inhibiting binding of a pro-neurotrophin to a Vps1 Op-domain receptor, in particular the binding of a pro-NGF or a pro-BDNF to a Sortilin receptor. The invention thus provides agents for the manufacture of a medicament, for treating and/or preventing disease or disorders such as but not limited to neurological, neuropsychiatric and ocular diseases, disorders, and degeneration as well as obesity, diabetes, pain and/or nociception in an individual.
    Type: Application
    Filed: April 25, 2014
    Publication date: January 22, 2015
    Applicant: H LUNDBECK A/S
    Inventors: Olav Michael Andersen, Anders Nykjaer
  • Publication number: 20150025008
    Abstract: The present invention generally relates to compositions, reagents and methods for detecting and treating a neural tube defect in a fetus. One aspect of the invention provides a method including administrating a composition containing noggin or LDN-193189 to the fetus in utero. In certain embodiments, the composition is administrated if the maternal blood or amniotic fluid contains an elevated amount of BMP4 and/or a reduced amount of noggin. In another aspect of the invention, the method includes administrating a composition containing GDC-0449 to the fetus in utero. In certain embodiments, the GDC-0449 is administrated if the maternal blood or amniotic fluid contains an elevated amount of sonic hedgehog.
    Type: Application
    Filed: July 15, 2014
    Publication date: January 22, 2015
    Inventors: Chandra Shekhar Mayanil, Elise Allender, Takao Tsurubuchi, Norman Ginsberg, David G. McLone, Tadanori Tomita
  • Publication number: 20150020222
    Abstract: The present invention generally relates to the field of treatment of neuronal disorders and more particularly to neurotrophic factor MANF and uses thereof. The present invention provides a pharmaceutical compound comprising MANF nucleic acid molecule, MANF protein or a functional fragment thereof for the treatment of a peripherial neuropathy including Alzheimer's disease, Parkinson's disease, epilepsy, drug addiction and ischemic brain injury.
    Type: Application
    Filed: September 9, 2014
    Publication date: January 15, 2015
    Applicant: HERANTIS PHARMA, PLC.
    Inventors: Mart SAARMA, Päivi LINDHOLM, Merja VOUTILAINEN, Johan PERÄNEN, Raimo TUOMINEN, Mikko AIRAVAARA, Veli-Matti LEPPÄNEN, Maria LINDAHL, Jaan-Olle ANDRESSOO
  • Patent number: 8933034
    Abstract: Composition containing a chimeric neuregulin polypeptides and method of making such polypeptides are disclosed. The chimeric neuregulin comprises a first moiety of at least 10 amino acids, wherein the first moiety is derived from a first polypeptide; and a second moiety of at least 5 amino acids, wherein the second moiety is derived from a second polypeptide; wherein the first polypeptide is a neuregulin and the chimeric neuregulin exhibits an enhanced binding affinity to integrin, Erb 3, or Erb 4 comparing to that of the first neuregulin.
    Type: Grant
    Filed: April 18, 2013
    Date of Patent: January 13, 2015
    Assignee: Brain-Gen Biotech
    Inventor: Byron D. Ford
  • Publication number: 20140377360
    Abstract: A composition for controlled release of a physiologically active substance can release a physiologically active substance in vivo at the desired timing. The composition includes an inner layer that is formed of a biodegradable substance that supports a physiologically active substance, and an outer layer that is formed of a biodegradable substance that differs from that of the inner layer.
    Type: Application
    Filed: November 9, 2012
    Publication date: December 25, 2014
    Applicant: National University Corporation University of Toyama
    Inventors: Tadashi Nakaji, Hiromi Kitano, Chirag Harsharan Singh Gujral
  • Publication number: 20140349930
    Abstract: The invention relates to treatments of neuropathic pain, including tactile allodynia, and to treatments for reducing loss of pain sensitivity associated with neuropathy. The present treatments involve the use of neublastin (NBN) polypeptides.
    Type: Application
    Filed: November 12, 2013
    Publication date: November 27, 2014
    Applicant: BIOGEN IDEC MA INC.
    Inventor: Dinah W. Y. Sah
  • Patent number: 8895507
    Abstract: Soluble proteins, e.g. Hevin, can trigger synapse formation; and other soluble proteins, e.g. SPARC antagonize this activity. Such proteins are synthesized in vitro and in vivo by astrocytes. Methods are provided for protecting or treating an individual suffering from adverse effects of deficits in synaptogenesis, or from undesirably active synaptogenesis.
    Type: Grant
    Filed: April 16, 2008
    Date of Patent: November 25, 2014
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Ben A. Barres, Cagla Eroglu
  • Patent number: 8883716
    Abstract: Devices and methods for treating diseases associated with loss of neuronal function are described. The methods are designed to promote proliferation, differentiation, migration, or integration of endogenous progenitor stem cells of the central nervous system (CNS). A therapy, such as an electrical signal or a stem cell enhancing agent, or a combination of therapies, is applied to a CNS region containing endogenous stem cells or a CNS region where the endogenous stem cells are predicted to migrate and eventually reside, or a combination thereof.
    Type: Grant
    Filed: December 7, 2011
    Date of Patent: November 11, 2014
    Assignee: Medtronic, Inc.
    Inventor: Lisa L. Shafer
  • Patent number: 8883728
    Abstract: Pharmaceutical compositions and methods for delivering a polypeptide to the central nervous system of a mammal via intranasal administration are provided. The polypeptide can be a catalytically active protein or an antibody, antibody fragment or antibody fragment fusion protein. The polypeptides are formulated with one or more specific agents.
    Type: Grant
    Filed: November 24, 2010
    Date of Patent: November 11, 2014
    Assignee: Aegis Therapeutics, LLC
    Inventor: Edward T. Maggio
  • Publication number: 20140315805
    Abstract: Methods of improving recovery of a mammal after an ischemic event (e.g., stroke) are provided. In various embodiments the methods involve administering a neural growth factor (e.g., BDNF) into the infarct (e.g., stroke) cavity in a biocompatible hydrogel formulation. In certain embodiments the hydrogel comprises a thiolated hyaluronan and a thiolated gelatin with an optional thiolated heparin.
    Type: Application
    Filed: March 1, 2012
    Publication date: October 23, 2014
    Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Stanley T. Carmichael, Andrew N. Clarkson
  • Patent number: 8858943
    Abstract: The present invention relates to methods of treating diseases or disorders affecting the eye or optic nerve characterized by elevated ?-amyloid levels or ?-amyloid deposits, particularly age related macular degeneration and glaucoma type diseases and ?-amyloid dependent cataract formation, with antigen binding proteins that bind ?-amyloid peptide and in particular human ?-amyloid peptide.
    Type: Grant
    Filed: September 23, 2008
    Date of Patent: October 14, 2014
    Assignee: Glaxo Group Limited
    Inventors: Stephen Anthony Burbidge, Ian Richard Catchpole, Jonathan Henry Ellis, Susannah Karen Ford, Volker Germaschewski, Umesh Kumar, Karen Louise Philpott, Peter Ernest Soden
  • Publication number: 20140296142
    Abstract: The present invention relates to a pharmaceutical composition for the prevention or treatment of diabetic neuropathy, wherein the pharmaceutical composition comprises, as active ingredients, different types of isoforms of HGF or a polynucleotide encoding the isoforms. The present invention is the first invention demonstrating that diabetic neuropathy can be prevented and treated using different types of isoforms of HGF. According to the present invention, it is possible to very effectively treat diabetic neuropathy.
    Type: Application
    Filed: March 27, 2012
    Publication date: October 2, 2014
    Applicant: VIROMED CO., LTD
    Inventors: Jong Mook Kim, Jae Gyun Jeong
  • Patent number: 8846615
    Abstract: The present invention relates to novel Motoneuronotrophic Factors (MNTF) peptides and analogs thereof, including compositions capable of promoting the growth and viability of neurons. MNTF peptides between two and six amino acids in length are provided, as well as analogs of these MNTF peptides that are modified by covalent attachment to another moiety. Other embodiments are described herein.
    Type: Grant
    Filed: February 23, 2009
    Date of Patent: September 30, 2014
    Assignee: Genervon Biopharmaceuticals, LLC
    Inventors: Pui-Yuk Dorothy Ko, Mark S. Kindy
  • Publication number: 20140271793
    Abstract: The instant invention provides electrospun fiber compositions comprising one or more polymers and one or more biologically active agents. In specific embodiments, the biologically active agents are nerve growth factors. In certain embodiments, the electrospun fiber compositions comprising one or more biologically active agents are on the surface of a film, or a tube. The tubes comprising the electrospun fiber compositions of the invention can be used, for example, as nerve guide conduits.
    Type: Application
    Filed: March 13, 2014
    Publication date: September 18, 2014
    Applicant: The Johns Hopkins University
    Inventors: Ahmet Hoke, Sing Y. Chew, Ruifa Mi, Kam W. Leong
  • Publication number: 20140274897
    Abstract: The present invention relates generally to methods for preventing and/or treating pancreatic disorders, particularly those related to diabetes, by administering a neurturin protein product.
    Type: Application
    Filed: May 27, 2014
    Publication date: September 18, 2014
    Applicant: EVOTEC INTERNATIONAL GMBH
    Inventors: Matthias Austen, Ulrike Burk
  • Patent number: 8822418
    Abstract: The invention provides, among other aspects, compositions and methods for treating, preventing, and diagnosing diseases or conditions associated with an abnormal level or activity of biglycan; diseases or conditions associated with an abnormal level or activity of collagen VI; disorders associated with an unstable cytoplasmic membrane, due, e.g., to an unstable dystrophin associated protein complex (DAPC); and disorders associated with abnormal synapses or neuromuscular junctions, including those resulting from an abnormal MuSK activation or acetylcholine receptor (AChR) aggregation.
    Type: Grant
    Filed: May 24, 2010
    Date of Patent: September 2, 2014
    Assignee: Brown University
    Inventors: Justin R. Fallon, Michael Rafii, Mark A. Bowe, Beth McKechnie, Alison Amenta, Mary Lynn Mercado, Hiroki Hagiwara
  • Publication number: 20140243264
    Abstract: The present invention provides methods of treating a retinal disorder comprising administering an effective amount of a neurotrophic factor to a subject having the retinal disorder. The neurotrophic factors useful in the invention include mesencephalic astrocyte-derived neurotrophic factor (MANF) and conserved dopamine neurotrophic factor (CDNF). The present invention further comprises pharmaceutical compositions and kits containing MANF and CDNF.
    Type: Application
    Filed: June 8, 2012
    Publication date: August 28, 2014
    Inventor: Rong Wen
  • Publication number: 20140227247
    Abstract: Composition containing a chimeric neuregulin polypeptides and method of making such polypeptides are disclosed. The chimeric neuregulin comprises a first moiety of at least 10 amino acids, wherein the first moiety is derived from a first polypeptide; and a second moiety of at least 5 amino acids, wherein the second moiety is derived from a second polypeptide; wherein the first polypeptide is a neuregulin and the chimeric neuregulin exhibits an enhanced binding affinity to integrin, Erb 3, or Erb 4 comparing to that of the first neuregulin.
    Type: Application
    Filed: April 18, 2013
    Publication date: August 14, 2014
    Inventor: Byron D. FORD
  • Patent number: 8796214
    Abstract: The present invention relates to a neurotrophic peptide having an amino acid sequence of VGDGGLFEKKL (SEQ ID NO:1) and alternatively comprising an adamantyl group at the C- and/or N-terminal end. The neurotrophic peptide can rescue cognition, correct impairments in neural cell proliferation and synaptic plasticity, and thus address the cognitive defects associated with Down syndrome.
    Type: Grant
    Filed: November 12, 2012
    Date of Patent: August 5, 2014
    Assignee: Research Foundation For Mental Hygiene, Inc.
    Inventors: Khalid Iqbal, Inge Grundke-Iqbal
  • Patent number: 8790666
    Abstract: The present invention relates to mechanically elongated neurons and provides useful compositions, devices and methods for treating a nerve lesion using such mechanically elongated neurons.
    Type: Grant
    Filed: May 5, 2006
    Date of Patent: July 29, 2014
    Assignee: The Trustees of the University of Pennsylvania
    Inventor: Douglas H. Smith
  • Patent number: 8779093
    Abstract: This invention relates to methods and compositions for detection and treatment of neurodegenerative diseases. In particular, the invention relates to polypeptides that can protect against neuron degeneration, nucleic acid molecules that encode such polypeptides, and antibodies that recognize said polypeptides.
    Type: Grant
    Filed: September 10, 2009
    Date of Patent: July 15, 2014
    Assignee: INSERM (Institut National de la Sante et de la Recherche Medicale)
    Inventors: Thierry Leveillard, Celine Jaillard, Jose-Alain Sahel
  • Patent number: 8772233
    Abstract: The present invention relates generally to methods for preventing and/or treating pancreatic disorders, particularly those related to diabetes, by administering a neurturin protein product.
    Type: Grant
    Filed: February 15, 2013
    Date of Patent: July 8, 2014
    Assignee: Evotec International GmbH
    Inventors: Matthias Austen, Ulrike Burk
  • Publication number: 20140135265
    Abstract: The present invention provides certain neuregulin peptides useful in, for example, methods and compositions comprising preventing, treating or delaying various diseases or disorders.
    Type: Application
    Filed: December 9, 2013
    Publication date: May 15, 2014
    Applicant: ZENSUN (SHANGHAI) SCIENCE & TECHNOLOGY LTD.
    Inventor: Mingdong ZHOU
  • Patent number: 8716223
    Abstract: A synthetic peptide sequence demonstrating neuroprotective and anti-inflammatory functions is disclosed. Methods of use for the synthetic peptide are also provided.
    Type: Grant
    Filed: May 5, 2009
    Date of Patent: May 6, 2014
    Assignee: Drexel University
    Inventors: Timothy J. Cunningham, Lihua Yao
  • Patent number: 8710005
    Abstract: A neuronal differentiation inducer provided by the present invention contains an artificially synthesized peptide which includes an amino acid sequence constituting a signal peptide in amyloid precursor protein (APP), or a partial sequence of the amino acid sequence constituting this signal peptide.
    Type: Grant
    Filed: April 12, 2010
    Date of Patent: April 29, 2014
    Assignee: Toagosei Co., Ltd.
    Inventors: Tetsuhiko Yoshida, Nahoko Kobayashi
  • Patent number: 8685925
    Abstract: The invention provides methods of treating stroke and related conditions exacerbated by fever and/or hyperglycemia by administering peptides or peptidomimetics that inhibit binding of NMDAR 2B to PSD-95 to a patient.
    Type: Grant
    Filed: July 10, 2007
    Date of Patent: April 1, 2014
    Assignee: Nono Inc.
    Inventor: Michael Tymianski
  • Publication number: 20140086897
    Abstract: Composition containing a chimeric neuregulin polypeptides and method of making such polypeptides are disclosed. The chimeric neuregulin comprises a first moiety of at least 10 amino acids, wherein the first moiety is derived from a first polypeptide; and a second moiety of at least 5 amino acids, wherein the second moiety is derived from a second polypeptide; wherein the first polypeptide is a neuregulin and the chimeric neuregulin exhibits an enhanced binding affinity to integrin, Erb 3, or Erb 4 comparing to that of the first neuregulin.
    Type: Application
    Filed: April 18, 2013
    Publication date: March 27, 2014
    Applicant: MOREHOUSE SCHOOL OF MEDICINE
    Inventor: Byron D. FORD
  • Publication number: 20140088009
    Abstract: Composition containing a chimeric neuregulin polypeptides and method of making such polypeptides are disclosed. The chimeric neuregulin comprises a first moiety of at least 10 amino acids, wherein the first moiety is derived from a first polypeptide; and a second moiety of at least 5 amino acids, wherein the second moiety is derived from a second polypeptide; wherein the first polypeptide is a neuregulin and the chimeric neuregulin exhibits an enhanced binding affinity to integrin, Erb 3, or Erb 4 comparing to that of the first neuregulin.
    Type: Application
    Filed: September 26, 2012
    Publication date: March 27, 2014
    Applicant: Morehouse School of Medicine
    Inventors: Byron D. Ford, James W. Lillard, JR.
  • Patent number: 8673852
    Abstract: The present disclosure relates to methods for treating neuronal disorders using a motoneuronotrophic factor (MNTF) or its peptide analogs. The present disclosure further relates to methods for treating a spinal cord injury, a neurodegenerative disease, a stroke or cerebral ischemia, Huntington's Disease, Parkinson's Disease, Multiple Sclerosis, amyotrophic lateral sclerosis (ALS), Alzheimer's Disease, and diabetic neuropathy in a subject by administration of motoneuronotrophic factor (MNTF) or its peptide analogs.
    Type: Grant
    Filed: November 13, 2007
    Date of Patent: March 18, 2014
    Assignee: Genervon Biopharmaceuticals, LLC
    Inventors: Pui-Yuk Dorothy Ko, Mark S. Kindy